463 related articles for article (PubMed ID: 20858994)
1. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
2. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
3. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
5. Existing and future therapeutic options for hepatitis C virus infection.
Bretner M
Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
[TBL] [Abstract][Full Text] [Related]
6. Current and future concepts in hepatitis C therapy.
Pawlotsky JM
Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
[TBL] [Abstract][Full Text] [Related]
7. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
8. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
Watashi K; Shimotohno K
Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
[TBL] [Abstract][Full Text] [Related]
9. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
Sarrazin C; Zeuzem S
Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus: prospects for future therapies.
Wilkinson T
Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis for responsiveness to anti-viral therapy in hepatitis C.
Polyak SJ; Gerotto M
Forum (Genova); 2000; 10(1):46-58. PubMed ID: 10717257
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
13. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
14. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
Watashi K
Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
[TBL] [Abstract][Full Text] [Related]
15. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibitors of hepatitis C virus replication.
Neyts J
Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
[TBL] [Abstract][Full Text] [Related]
18. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
Helmy A
Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
[TBL] [Abstract][Full Text] [Related]
19. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies.
Berenguer M; Wright TL
Proc Assoc Am Physicians; 1998; 110(2):98-112. PubMed ID: 9542765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
